CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing small molecule inhibitors targeting Proprotein Convertases, which are essential for the activation of the SARS-CoV-2 virus. By employing innovative screening methods, the project aims to create effective treatments against COVID-19 and potentially other emerging pathogens.
The novel SARS-CoV-2 is a lethal human pathogen with no FDA approved vaccines or drugs.
An important step of the virus life-cycle is the viral glycoprotein S activation by Proprotein Convertases (PCs) which are proteases with a broad spectrum of cellular substrates.
Inhibition of the processing step locks the virus into a form which eventually is no more pathogenic.
Therefore, PCs represent attractive drug targets to fight against SARS-CoV-2.
To date, there are no PCs inhibitors available for th…
UNIVERSITA DEGLI STUDI DI PADOVA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
